20-035 Phase II
A Multi-Center, Open Label Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors (View details on clinicaltrial.gov)
Search Cancer Clinical Trials
The Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
18 results
19-422 Phase I
A Phase 1 First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (View details on clinicaltrial.gov)
20-560 Phase I
A Phase 1 Study of Oral LY3410738 in Patients with Advanced Hematologic Malignancies with IDH1 or IDH2 Mutations (View details on clinicaltrial.gov)
20-191 Phase I
A Phase 1 Study of SEA-CD70 in Myeloid Malignancies (View details on clinicaltrial.gov)
21-250 Phase I
A Phase 1, Multicenter, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered FHD-286 in Subjects with Advanced Hematologic Malignancies (View details on clinicaltrial.gov)
14-191 Phase I
A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients with Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 with and without Ruxolitinib in Patients with Myelofibrosis) (View details on clinicaltrial.gov)
21-706 Phase II
A PHASE 1B, OPEN-LABEL, GLOBAL, MULTICENTER, DOSE DETERMINATION STUDY TO EVALUATE SAFETY, TOLERABILITY, AND PRELIMINARY EFFICACY OF CC-486 (ONUREG®) IN COMBINATION THERAPY IN SUBJECTS WITH ACUTE MYELOID LEUKEMIA (AML) (View details on clinicaltrial.gov)
21-113 Phase II
A Phase 2 Randomized Study Comparing Venetoclax and Azacitidine to Induction Chemotherapy for Newly Diagnosed Fit Adults with Acute Myeloid Leukemia (View details on clinicaltrial.gov)
21-132 Phase II
A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With Advanced Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) (View details on clinicaltrial.gov)
19-087 Phase I
A Phase I Clinical Trial with CAR-37 T Cells for the Treatment of Patients with Relapsed or Refractory CD37+ Hematologic Malignancies (View details on clinicaltrial.gov)
Showing 1 - 10 of 18 results